Leo Pharma A/S, of Ballerup, Denmark, said the EU granted scientific approval for Enstilar (calcipotriol/betamethasone dipropionate 50 mcg/g / 0,5 mg/g), an alcohol-free foam product to treat psoriasis vulgaris for those 18 and older in the EU. The approval was based on data from the phase IIIa PSO-FAST study.